All Retinitis Pigmentosa (RP) articles
-
NewsNobel Prize awarded for optogenetics
The 2026 Nobel Prize in Physiology or Medicine award celebrates a key advancement in neuroscience following breakthrough findings from a 2005 research paper.
-
NewsLong-term potential revealed for novel modifier gene therapy
The positive two-year findings from the Phase I/II gene therapy trial in retinitis pigmentosa reiterate the potential of mutation-agnostic therapies.
-
ArticleModifier gene therapy - clinical development and manufacturing considerations
Expanding on his earlier podcast discussion with EPR, Dr Arun Upadhyay, Chief Scientific Officer and Head of Research & Development at Ocugen, discusses the company’s promising modifier gene therapy candidates for ophthalmic disorders.